DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,964,813 | -31.4% | 289,133 | -1.9% | 0.04% | -27.1% |
| Q2 2023 | $8,699,282 | +24.6% | 294,791 | -2.7% | 0.05% | +17.1% |
| Q1 2023 | $6,980,000 | -23.2% | 302,961 | -7.9% | 0.04% | -26.8% |
| Q4 2022 | $9,092,000 | +16.0% | 329,084 | +28.8% | 0.06% | +9.8% |
| Q3 2022 | $7,840,000 | +1.0% | 255,460 | -3.1% | 0.05% | +4.1% |
| Q2 2022 | $7,760,000 | +18.3% | 263,704 | +29.4% | 0.05% | +44.1% |
| Q1 2022 | $6,557,000 | -24.0% | 203,850 | +6.4% | 0.03% | -10.5% |
| Q4 2021 | $8,627,000 | -29.5% | 191,516 | -21.0% | 0.04% | -30.9% |
| Q3 2021 | $12,236,000 | -46.4% | 242,545 | -16.7% | 0.06% | -43.9% |
| Q2 2021 | $22,834,000 | +28.4% | 291,103 | -8.4% | 0.10% | +24.1% |
| Q1 2021 | $17,778,000 | -29.1% | 317,862 | +6.2% | 0.08% | -44.0% |
| Q4 2020 | $25,059,000 | – | 299,186 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |